Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F24%3A00599113" target="_blank" >RIV/68081707:_____/24:00599113 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/24:73626136 RIV/00098892:_____/24:10158792
Result on the web
<a href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1394292/full" target="_blank" >https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1394292/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fonc.2024.1394292" target="_blank" >10.3389/fonc.2024.1394292</a>
Alternative languages
Result language
angličtina
Original language name
Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers
Original language description
Background Prostate cancer is the second leading cause of male cancer-related deaths in Western countries, which is predominantly attributed to the metastatic castration-resistant stage of the disease (CRPC). There is an urgent need for better prognostic and predictive biomarkers, particularly for androgen receptor targeted agents and taxanes.Methods We have searched the PubMed database for original articles and meta-analyses providing information on blood-based markers for castration-resistant prostate cancer monitoring, risk group stratification and prediction of therapy response.Results The molecular markers are discussed along with the standard clinical parameters, such as prostate specific antigen, lactate dehydrogenase or C-reactive protein. Androgen receptor (AR) alterations are commonly associated with progression to CRPC. These include amplification of AR and its enhancer, point mutations and splice variants. Among DNA methylations, a novel 5-hydroxymethylcytosine activation marker of TOP2A and EZH2 has been identified for the aggressive disease. miR-375 is currently the most promising candidate among non-coding RNAs and sphingolipid analysis has recently emerged as a novel approach.Conclusions The promising biomarkers have the potential to improve the care of metastatic prostate cancer patients, however, they need further validation for routine implementation.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Oncology
ISSN
2234-943X
e-ISSN
2234-943X
Volume of the periodical
14
Issue of the periodical within the volume
SEP 10 2024
Country of publishing house
CH - SWITZERLAND
Number of pages
14
Pages from-to
1394292
UT code for WoS article
001322052900001
EID of the result in the Scopus database
2-s2.0-85204909356